Tuesday , May 23 2017
Breaking News
Home / Business / Alembic Pharmaceuticals gets final USFDA nod for hypertension drug

Alembic Pharmaceuticals gets final USFDA nod for hypertension drug

Alembic Pharmaceuticals has received final approvals from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Applications (ANDAs) for Olmesartan Medoxomil Tablets, 5 mg, 20mg and 40mg and Olmesartan Medoxomil with Hydrochlorothiazide Tablets 20/12.5mg, 40/12.5mg and 40/25mg.

The approved ANDAs are therapeutically equivalent to the reference listed drug products (RLDs) Benicar Tablets 5mg, 20mg and 40mg and Benicar HCT Tablets, 20/12.5mg, 40/12.5mg and 40/25mg, of Daiichi Sankyo Inc. The approved ANDAs are indicated for the treatment of hypertension.

According to IMS, Benicar and Benicar HCT have an estimated market size of $1.8 billion for twelve months ending December 2016. Alembic now has a total of 55 ANDA approvals (49 final approvals and 6 tentative approvals) from the USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.

About editor

Leave a Reply

Your email address will not be published. Required fields are marked *

*

Close